| Quarter (USD) | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 224.80 mm | 224.80 mm | 224.80 mm | 224.80 mm | 224.80 mm | 224.80 mm |
| Cash burn (monthly) | 54.03 mm | (no burn) | 51.14 mm | 52.02 mm | 40.17 mm | 37.67 mm |
| Cash used (since last report) | 2.00 bn | n/a | 1.89 bn | 1.92 bn | 1.49 bn | 1.39 bn |
| Cash remaining | -1.77 bn | n/a | -1.67 bn | -1.70 bn | -1.26 bn | -1.17 bn |
| Runway (months of cash) | -32.8 | n/a | -32.6 | -32.7 | -31.4 | -31.0 |
| 13F holders | Current |
|---|---|
| Total holders | 0 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 0.00 |
| Total shares | 0.00 |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 25 Jan 24 | Arena Pharmaceuticals | Voting Common Stock | Sell | Dispose S | No | No | 24.25 | 3,978,540 | 96.48 mm | 0 |
